He (Howard) Zhang
About
Research
Publications
2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk D. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. New England Journal Of Medicine 2024 PMID: 39453772, DOI: 10.1056/nejmoa2410316.Peer-Reviewed Original ResearchProtein-to-creatinine ratioUrinary protein-to-creatinine ratioIgA nephropathyMonth 9Biopsy-confirmed IgA nephropathySupportive therapyTreatment periodDouble-blind treatment periodSecondary end point analysisTrial populationIncidence of adverse eventsIncreased risk of infectionPlacebo-controlled trialSecondary end pointsComplement pathway inhibitionProportion of patientsPathogenesis of IgA nephropathyKidney replacement therapyClinically meaningful reductionsInterim efficacy analysisRisk of infectionDouble-blindPlacebo groupSafety findingsEfficacy analysisAtrasentan in Patients with IgA Nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Lodha A, Gray T, Wang Y, Renfurm R, Barratt J. Atrasentan in Patients with IgA Nephropathy. New England Journal Of Medicine 2024 PMID: 39460694, DOI: 10.1056/nejmoa2409415.Peer-Reviewed Original ResearchIgA nephropathyAdverse eventsInterim analysisBiopsy-proven IgA nephropathyInterim analysis of dataBaseline to weekBody-surface areaPercentage of patientsProtein-to-creatinine ratioUrinary protein-to-creatinine ratioMean percentage changeCases of cardiac failureRisk of kidney failureClinically meaningful reductionsTrial regimenPlacebo groupAntagonist atrasentanDouble-blindBetween-group differencesCardiac failureReduce proteinuriaFluid retentionSevere proteinuriaAtrasentan groupAtrasentanEfficacy and Safety of Nefecon in Patients with Immunoglobulin A Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.
Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, Kristensen J, Barratt J. Efficacy and Safety of Nefecon in Patients with Immunoglobulin A Nephropathy from Mainland China: 2-Year NefIgArd Trial Results. Kidney360 2024 PMID: 39383260, DOI: 10.34067/kid.0000000583.Peer-Reviewed Original ResearchEfficacy end pointImmunoglobulin A nephropathyEnd pointsImmune-mediated kidney diseasesGlobal study populationNo severe infectionsPreservation of eGFRIgAN pathophysiologyPrimary IgANDouble-blindEGFR reductionConsistent with global studiesEfficacy outcomesNo deathsAdverse eventsSevere infectionsChina cohortFollow-upPlaceboKidney diseaseSafety signalsBudesonide formulationIgANSupportive carePatientsNeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial
Lafayette R, Kristensen J, Jones R, Floege J, Tesar V, Trimarchi H, Reich H, Zhang H, Rovin B, Barratt J. NeflgArd Open-Label Extension: Efficacy and Safety of Nefecon in Patients with IgAN Who Completed the 2-Year Phase 3 Trial. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024c9ebnjqe. DOI: 10.1681/asn.2024c9ebnjqe.Peer-Reviewed Original ResearchStudy design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Noronha I, Trimarchi H, Hou F, Renfurm R, Gray T, Camargo M, Barratt J. Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgA nephropathy. Kidney International Reports 2024 DOI: 10.1016/j.ekir.2024.10.004.Peer-Reviewed Original ResearchRenin-angiotensin system inhibitorsEndothelin-AStable doseIgA nephropathyEndothelin-A receptor antagonistSodium-glucose cotransporter-2 inhibitorsPlacebo-controlled clinical trialRenin-angiotensin system inhibitor therapyBiopsy-proven IgANBaseline to weekCotransporter-2 inhibitorsMethods Eligibility criteriaKidney function lossRandomized controlled studyDouble-blindReceptor antagonistReduce proteinuriaEGFR changeBaseline characteristicsSystem inhibitorsIgAN populationAtrasentanKidney functionKidney inflammationClinical trialsTargeting APRIL in the treatment of glomerular diseases
Cheung C, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesař V, Trimarchi H, Wong M, Zhang H, Rizk D. Targeting APRIL in the treatment of glomerular diseases. Kidney International 2024, 106: 806-818. PMID: 39182759, DOI: 10.1016/j.kint.2024.08.012.Peer-Reviewed Original ResearchGlomerular diseaseB cell depletion strategiesCytokine B cell-activating factorDeleterious host immune responsesFunctionality of humoral immunityMemory B-cell functionB-cell activating factorProliferation inducing ligandTreatment of glomerular diseasesB cell functionB cell developmentB cell survivalImmunoglobulin class switchingResponse to vaccinationClinical trial dataHost immune responseTumour necrosis factor (TNF)-superfamilyImmunomodulatory approachesAutoimmune diseasesClinical developmentInducing ligandIgA nephropathyHumoral immunityTherapeutic inhibitionClass switchingThe pathogenesis of IgA nephropathy and implications for treatment
Cheung C, Alexander S, Reich H, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nature Reviews Nephrology 2024, 21: 9-23. PMID: 39232245, PMCID: PMC7616674, DOI: 10.1038/s41581-024-00885-3.Peer-Reviewed Original ResearchIgA nephropathyComplement activationDisease pathogenesisB cell primingMucosal immune systemPathogenesis of IgA nephropathyChronic kidney diseaseTargeting different pathwaysPlasma cellsPrimary glomerulonephritisTreatment optionsIgA antibodiesKidney diseaseImmune complexesTriggering inflammationKidney damageGut mucosaObservational studyKidney failureImmune systemLong-term outlookPathway activationPathogenesisIgANNephropathyA Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome
Song Z, Li Y, Zhang H, Zhou X. A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome. Kidney International Reports 2024, 9: 3067-3069. PMID: 39430195, PMCID: PMC11489420, DOI: 10.1016/j.ekir.2024.07.027.Peer-Reviewed Original ResearchCurrent understanding and new insights in the treatment of IgA nephropathy
Zhang Y, Zhang H. Current understanding and new insights in the treatment of IgA nephropathy. Nephrology 2024, 29: 75-79. PMID: 38958055, DOI: 10.1111/nep.14340.Peer-Reviewed Original ResearchIgA nephropathyProgression to end-stage kidney diseaseRisk of progression to end-stage kidney diseaseTreatment of IgA nephropathyEra of targeted treatmentCurrent treatment strategiesEnd-stage kidney diseaseDownstream complement activationDevelopment of IgANRandomized controlled trialsImmunosuppressive approachesPotential therapeutic targetPrimary glomerulonephritisKDIGO guidelinesOff-labelTreatment strategiesKidney diseaseIgANPathogenic mechanismsControlled trialsTreatment approachesComplement activationDisease pathogenesisTherapeutic targetNephropathyCirculating Proteins and IgA Nephropathy
Tang C, Chen P, Xu L, Lv J, Shi S, Zhou X, Liu L, Zhang H. Circulating Proteins and IgA Nephropathy. Journal Of The American Society Of Nephrology 2024, 35: 1045-1057. PMID: 38687828, PMCID: PMC11377805, DOI: 10.1681/asn.0000000000000379.Peer-Reviewed Original ResearchProtein-protein interaction networkProtein-disease pairsColocalization analysisInteraction networkEast Asian ancestryMendelian randomizationPotential drug targetsDrug repurposing opportunitiesVariant annotationAncestry populationsIdentified proteinsNetwork Mendelian randomizationMendelian randomization studiesAsian ancestryDrug targetsProteinAncestryEast AsiansTherapeutic targetColocalizationCirculating proteinsCausal effectsMedicationTargetAnnotation